ANCHOR Trial Conclusions Regarding the Effects of Pure Eicosapentaenoic Acid on Low-Density Lipoprotein Cholesterol
In the ANCHOR trial publication, Ballantyne et al, evaluating AMR101 (icosapent ethyl) for the treatment of mixed dyslipidemia, concluded that omega-3 fatty acids containing only eicosapentaenoic acid (EPA) lower low-density lipoprotein…